| Japanese |
|---|
| Title | 転移性骨腫瘍診断における骨吸収マーカー (ICTP) と骨形成マーカー (PICP) の役割 |
|---|
| Subtitle | 技術報告 |
|---|
| Authors | 小泉満*, 山田康彦*, 滝口智洋*, 鈴木千春*, 明石知篤*, 野村悦司*, 山下孝*, 尾形悦郎** |
|---|
| Authors(kana) | |
|---|
| Organization | *癌研究会附属病院アイソトープ部, **内科 |
|---|
| Journal | 核医学 |
|---|
| Volume | 33 |
|---|
| Number | 1 |
|---|
| Page | 77-84 |
|---|
| Year/Month | 1996/1 |
|---|
| Article | 報告 |
|---|
| Publisher | 日本核医学会 |
|---|
| Abstract | 「要旨」骨吸収マーカーの一つとされているI型コラーゲン代謝産物である血中ピリジノリン架橋I型コラーゲンC端テロペプチド(ICTP)および血中I型プロコラーゲンのC端プロペプチド(PICP)を乳癌, 前立腺癌, 肺癌症例で, 骨シンチグラフィ施行時に測定した. ICTP, PICPは骨転移症例で骨転移の程度が増悪するに従い高値を示した. ただし骨転移の程度の軽い症例では統計的な有意差を認めなかった. 骨転移の診断におけるカットオフ値はICTPでは5.0 ng/ml, PICPでは140 ng/mlが適当と考えられた. ICTPは骨転移の診断に関して, 肺癌では感度, 特異度ともに優れており, 乳癌では感度, 特異度ともPICPに較べ優れていた. PICPは, 前立腺癌でICTPとほぼ同等な成績が得られた. |
|---|
| Practice | 臨床医学：一般 |
|---|
| Keywords | Metastatic bone tumor, Bone metabolic markers, ICTP, PICP, Bone scan. |
|---|
| English |
|---|
| Title | Serum Concentration of Pyridinoline Cross-linked Carboxy-terminal Telopeptide of Type-I Collagen (ICTP) and Carboxyterminal Propeptide of Human Type I Procollagen (PICP) in the Diagnosis of Bone Metastases |
|---|
| Subtitle | |
|---|
| Authors | Mitsuru KOIZUMI*, Yasuhiko YAMADA*, Tomohiro TAKIGUCHI*, Chiharu SUZUKI*, Tomoatsu AKASHI*, Etsuji NOMURA*, Takashi YAMASHITA*, Etsuro OGATA** |
|---|
| Authors(kana) | |
|---|
| Organization | *Department of Nuclear Medicine, **Department of Internal Medicine, Cancer Institute Hospital |
|---|
| Journal | The Japanese Journal of nuclear medicine |
|---|
| Volume | 33 |
|---|
| Number | 1 |
|---|
| Page | 77-84 |
|---|
| Year/Month | 1996/1 |
|---|
| Article | Report |
|---|
| Publisher | THE JAPANESE SOCIETY OF NUCLEAR MEDICINE |
|---|
| Abstract | [Summary]Recently discovered bone metabolic markers are expected to play an additional role in the diagnosis of bone metastasis. We measured bone metabolic markers, serum pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen (ICTP) and carboxyterminal propeptide of human type I procollagen (PICP) in 224 patients with breast cancer (106 with bone metastases), 61 petients with prostatic cancer (30 with bone metastases), 45 patients with lung cancer (17 with bone metastases) and 13 patients with miscellaneous cancers (7 with bone metastasis) and compared the values in the presence and absence of bone metastasis. ICTP and PICP increased significantly in patients with bone metastases. By the analysis of sensitivity and specificity, the cut-off levels were considered to be 5.0 ng/ml for ICTP and 140 ng/ml for PICP. In lung cancer (bone metastases are mostly of osteolytic), ICTP was excellent marker in detecting bone metastasis. In breast cancer (bone metastases are mostly of mixed type), ICTP was good in detecting bone metastases. In prostatic cancer (bone metastases are mostly of osteoblastic), ICTP and PICP were good markers in detecting high grade of bone metastases. Over all, ICTP was more sensitive in the diagnosis of bone metastases than PICP. However, both markers were not effective in detecting low grade bone metastases. ICTP and PICP should play a supportive role to imaging modalities in the diagnosis of bone metastases. |
|---|
| Practice | Clinical medicine |
|---|
| Keywords | Metastatic bone tumor, Bone metabolic markers, ICTP, PICP, Bone scan. |
|---|